ST Pharm, a manufacturer of pharmaceutical ingredients, has recently announced that it has entered into a joint venture with its Japanese competitors Fujimoto Chemical Products and trading company Inabata & Co., Ltd. to license technology and establish a joint venture for the production of oligonucleotides (hereinafter referred to as oligos).